What is a common use for SGLT2 inhibitors in chronic kidney disease?

SGLT2 inhibitors, a class of medications primarily used in the management of diabetes, are commonly utilized in patients with chronic kidney disease (CKD) to improve glycemic control, especially for those who also have type 2 diabetes. These agents work by inhibiting the sodium-glucose cotransporter 2 in the kidneys, leading to decreased reabsorption of glucose and increased urinary glucose excretion. This mechanism not only helps in lowering blood glucose levels but also has favorable effects on weight and blood pressure, which are important considerations in the management of patients with CKD.

Additionally, recent studies have shown that SGLT2 inhibitors provide renal protective benefits, reducing the risk of progression to end-stage renal disease and cardiovascular events in patients with CKD and diabetes. This dual benefit of improving glycemic control while also supporting kidney function makes SGLT2 inhibitors particularly valuable in this patient population.

Other options do not directly address the primary role of SGLT2 inhibitors in CKD. For example, while managing hyperlipidemia is important in CKD, it is not a primary indication for SGLT2 inhibitors. Enhancing bone health is typically approached with other medications, and increasing uric acid excretion is more relevant to